The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer

被引：7
作者：
Santana-Davila, Rafael [1 ]
Chow, Laura Q. M. [1 ]
机构：
[1] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA 98195 USA
来源：
FUTURE ONCOLOGY | 2018年 / 14卷 / 03期
关键词：
chemo-immunotherapy; first-line; immune checkpoint inhibitors; immunotherapy; lung cancer; NSCLC; treatment naive; PACLITAXEL PLUS CARBOPLATIN; OPEN-LABEL; PHASE-III; PEMBROLIZUMAB; NIVOLUMAB; DOCETAXEL; CHEMOTHERAPY; MULTICENTER; IPILIMUMAB;
D O I：
10.2217/fon-2017-0124
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：191 / 194
页数：4
相关论文
共 50 条
  • [21] Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H
    Gubens, Matthew A.
    Sequist, Lecia V.
    Stevenson, James P.
    Powell, Steven F.
    Villaruz, Liza C.
    Gadgeel, Shirish M.
    Langer, Corey J.
    Patnaik, Amita
    Borghaei, Hossein
    Jalal, Shadia I.
    Fiore, Joseph
    Saraf, Sanatan
    Raftopoulos, Harry
    Gandhi, Leena
    LUNG CANCER, 2019, 130 : 59 - 66
  • [22] Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis
    Maniadakis, N.
    Fragoulakis, V.
    Pallis, A. G.
    Simou, E.
    Georgoulias, V.
    ANNALS OF ONCOLOGY, 2010, 21 (07) : 1462 - 1467
  • [23] Combining Immunotherapy with Radiation Therapy in Non- Small Cell Lung Cancer
    Fitzgerald, Kelly
    Simone, Charles B., II
    THORACIC SURGERY CLINICS, 2020, 30 (02) : 221 - 239
  • [24] Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy
    Sun, Lova
    Davis, Christiana W.
    Hwang, Wei-Ting
    Jeffries, Seth
    Sulyok, Lydia Frenzel
    Marmarelis, Melina E.
    Singh, Aditi P.
    Berman, Abigail T.
    Feigenberg, Steven J.
    Levin, William
    Ciunci, Christine A.
    Bauml, Joshua M.
    Cohen, Roger B.
    Langer, Corey J.
    Aggarwal, Charu
    CLINICAL LUNG CANCER, 2021, 22 (01) : 58 - +
  • [25] New options on the horizon for nononcogene addicted non-small-cell lung cancer
    Paglialunga, Luca
    Ricciardi, Serena
    D'Arcangelo, Manolo
    FUTURE ONCOLOGY, 2018, 14 (13) : 19 - 28
  • [26] Immunotherapy in advanced non-small-cell lung cancer withEGFRmutations
    Liu, Fangfang
    Yuan, Xun
    Jiang, Jizong
    Chu, Qian
    IMMUNOTHERAPY, 2020, 12 (16) : 1195 - 1207
  • [27] Targeting PD-L1 for non-small-cell lung cancer
    Feld, Emily
    Horn, Leora
    IMMUNOTHERAPY, 2016, 8 (06) : 747 - 758
  • [28] Neoadjuvant immunotherapy in resectable non-small-cell lung cancer
    Chen, Lanyi Nora
    Wei, Alexander Z.
    Shu, Catherine A.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [29] First line Immunotherapy for Non-Small Cell Lung Cancer
    Nasser, Nicola J.
    Gorenberg, Miguel
    Agbarya, Abed
    PHARMACEUTICALS, 2020, 13 (11) : 1 - 24
  • [30] Update 2025: Management of Non-Small-Cell Lung Cancer
    Jeon, Hyein
    Wang, Shuai
    Song, Junmin
    Gill, Harjot
    Cheng, Haiying
    LUNG, 2025, 203 (01)
12345